Cobas Ampliprep/Cobas Taqman Hiv-1 Test: For in Vitro Diagnostic Use

COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
FOR IN VITRO DIAGNOSTIC USE.
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test HIMCAP 48 Tests P/N: 03542998 190
COBAS® AmpliPrep/COBAS® TaqMan® PG WR 5.1 Liters P/N: 03587797 190
Wash Reagent
INTENDED USE
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is an in vitro nucleic acid amplification test for
the quantitation of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma using the
COBAS® AmpliPrep Instrument for automated specimen processing and COBAS® TaqMan® Analyzer or
COBAS® TaqMan® 48 Analyzer for automated amplification and detection.
This test is intended for use in conjunction with clinical presentation and other laboratory markers of dis
ease progress for the clinical management of HIV-1 infected patients. The Test can be used to assess patient
prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by
measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is not intended for use as a screening test for the
presence of HIV-1 in blood or blood products or as a diagnostic test to confirm the presence of HIV-1
infection.
The test can quantitate HIV-1 RNA over the range of 48 - 10,000,000 copies/mL. One copy of HIV-1 RNA
is equivalent to 1.7 ± 0.1 International Units (IU) based on the WHO 1st International Standard for HIV-1
RNA for Nucleic Acid-Based Techniques (NAT) (NIBSC 97/656).
SUMMARY AND EXPLANATION OF THE TEST
Human Immunodeficiency Virus (HIV) is the etiologic agent of Acquired Immunodeficiency Syndrome
(AIDS)1-3. HIV infection can be transmitted by sexual contact, exposure to infected blood or blood prod
ucts, or by an infected mother to the fetus4. Within three to six weeks of exposure to HIV, infected individ
uals generally develop a brief, acute syndrome characterized by flu-like symptoms and associated with high
levels of viremia in the peripheral blood5-8. In most infected individuals this is followed by an HIV-specific
immune response and a decline of plasma viremia, usually within four to six weeks of the onset of symp
toms9,10. After seroconversion, infected individuals typically enter a clinically stable, asymptomatic phase
that can last for years11-13. The asymptomatic period is characterized by persistent, low level plasma
viremia14 and a gradual depletion of CD4+ T lymphocytes, leading to severe immunodeficiency, multiple
opportunistic infections, malignancies and death15. Although virus levels in the peripheral blood are rela
tively low during the asymptomatic phase of the infection, virus replication and clearance appear to be
dynamic processes in which high rates of virus production and infection of CD4+ cells are balanced by
equally high rates of virus clearance, death of infected cells and replenishment of CD4+ cells, resulting in
relatively stable levels of both plasma viremia and CD4+ cells16-18.
Quantitative measurements of HIV viremia in the peripheral blood have shown that higher virus levels may
be correlated with increased risk of clinical progression of HIV disease, and that reductions in plasma virus
levels may be associated with decreased risk of clinical progression19-21. Virus levels in the peripheral blood
can be quantitated by measurement of the HIV p24 antigen in serum, by quantitative culture of HIV from
plasma, or by direct measurement of viral RNA in plasma using nucleic acid amplification or signal ampli
fication technologies22-26.
p24 antigen is the principal core protein of HIV and is found in serum either free or bound by anti-p24 anti
body. Free p24 antigen can be measured with commercially available enzyme immunoassays (EIA), although
the usefulness of p24 antigen as a marker of viral load is limited since the antigen is detectable in only 20%
of asymptomatic patients and 40-50% of symptomatic patients. Procedures to dissociate antigen-antibody
complexes improve the sensitivity of the p24 antigen tests, but the viral protein remains undetectable in
most asymptomatic patients22.
Infectious HIV in plasma can be cultured by inoculation into activated peripheral blood mononuclear cells
(PBMC) from normal donors. Quantitation is achieved by inoculating PBMC with serial dilutions of the
plasma specimen. Quantitative culture has limited utility for monitoring virus levels in infected individuals
since only a small fraction of virus particles is infectious in vitro. Infectious virus is often undetectable in
asymptomatic individuals22.
HIV RNA in plasma can be quantitated by nucleic acid amplification technologies, such as the Polymerase
Chain Reaction (PCR)27-29. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test uses PCR technology
to achieve high sensitivity and dynamic range for the quantitative detection of HIV-1 RNA in EDTA anti
coagulated plasma.
PRINCIPLES OF THE PROCEDURE

The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is a nucleic acid amplification test for the quantita
tion of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma. Specimen preparation is auto
mated using the COBAS® AmpliPrep Instrument with amplification and detection automated using the
COBAS® TaqMan® Analyzer or the COBAS® TaqMan® 48 Analyzer.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is based on three major processes: (1) specimen
preparation to isolate HIV-1 RNA; (2) reverse transcription of the target RNA to generate complementary DNA
(cDNA), and (3) simultaneous PCR amplification of target cDNA and detection of cleaved dual-labeled
oligonucleotide probe specific to the target.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test permits automated specimen preparation followed
by automated reverse transcription, PCR amplification and detection of HIV-1 target RNA and HIV-1
Quantitation Standard (QS) Armored RNA. The Master Mix reagent contains primers and probes specific
for both HIV-1 RNA and HIV-1 QS RNA. The Master Mix has been developed to ensure equivalent quan
titation of group M subtypes of HIV-1. The detection of amplified DNA is performed using a target-specific
and a QS-specific dual-labeled oligonucleotide probe that permit independent identification of HIV-1
amplicon and HIV-1 QS amplicon.
The quantitation of HIV-1 viral RNA is performed using the HIV-1 QS. It compensates for effects of inhi
bition and controls the preparation and amplification processes, allowing a more accurate quantitation of
HIV-1 RNA in each specimen. The HIV-1 QS is a non-infectious Armored RNA construct that contains
HIV sequences with identical primer binding sites as the HIV-1 target RNA and a unique probe binding
region that allows HIV-1 QS amplicon to be distinguished from HIV-1 target amplicon.
The HIV-1 QS is added to each specimen at a known copy number and is carried through the specimen prepa
ration, reverse transcription, PCR amplification and detection steps of cleaved dual-labeled oligonucleotide
detection probes. The COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer calculates the HIV-1
RNA concentration in the test specimens by comparing the HIV-1 signal to the HIV-1 QS signal for each spec
imen and control.
Target Selection
Selection of the target RNA sequence for HIV-1 depends on identification of regions within the HIV-1 genome
that show maximum sequence conservation among the various group M HIV-1 subtypes. Generic silica based
specimen preparation is used to capture the HIV-1 RNA and HIV-1 QS RNA and defined oligonucleotides are
used as primers in amplification of the HIV-1 RNA and HIV-1 QS RNA. A target-specific and a QS-specific
dual-labeled oligonucleotide probe permit independent identification of HIV-1 amplicon and HIV-1 QS
amplicon. Accordingly, the appropriate selection of the primers and the dual-labeled oligonucleotide probe
is critical to the ability of the test to amplify and detect the HIV-1 subtypes. The COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test uses reverse transcription and PCR amplification primers that define a sequence within
the highly conserved region of the HIV-1 gag gene32. The gag region encodes the group-specific antigens or
core structural proteins of the virion. The nucleotide sequence of the primers has been optimized to yield
comparable amplification of group M subtypes of HIV-1.
Specimen Preparation
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test utilizes automated specimen preparation on the
COBAS® AmpliPrep Instrument by a generic silica-based capture technique. The procedure processes 850
µL of plasma. The HIV-1 virus particles are lysed by incubation at elevated temperature with a protease and
chaotropic lysis/binding buffer that releases nucleic acids and protects the released HIV-1 RNA from RNases
in plasma. Protease and a known number of HIV-1 QS Armored RNA molecules are introduced into each
specimen along with the lysis reagent and magnetic glass particles. Subsequently, the mixture is incubated
and the HIV-1 RNA and HIV-1 QS RNA are bound to the surface of the magnetic glass particles. Unbound
substances, such as salts, proteins and other cellular impurities, are removed by washing the magnetic glass
particles. After separating the magnetic glass particles and completing the washing steps, the adsorbed
nucleic acids are eluted at elevated temperature with an aqueous solution. The processed specimen, con
taining the magnetic glass particles as well as released HIV-1 RNA and HIV-1 QS RNA, is added to the
amplification mixture and transferred to the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer.
The HIV-1 target RNA and the HIV-1 QS RNA are then reverse transcribed, amplified and simultaneously
detected by cleavage of a target-specific and a QS-specific dual-labeled oligonucleotide probe.

Reverse Transcription and PCR Amplification
The reverse transcription and PCR amplification reaction is performed with the thermostable recombinant
enzyme Thermus specie DNA Polymerase (Z05). In the presence of manganese (Mn2+) and under the appro
priate buffer conditions, Z05 has both reverse transcriptase and DNA polymerase activity30,31. This allows
both reverse transcription and PCR amplification to occur together with real-time detection of the amplicon.
Processed specimens are added to the amplification mixture in amplification tubes (K-tubes) in which
both reverse transcription and PCR amplification occur. The reaction mixture is heated to allow a down
stream primer to anneal specifically to the HIV-1 target RNA and to the HIV-1 QS RNA. In the presence
of Mn2+ and excess deoxynucleotide triphosphates (dNTPs), including deoxyadenosine, deoxyguanosine,
deoxycytidine, deoxyuridine and deoxythymidine triphosphates, Z05 polymerase extends the annealed
primers forming a DNA strand complementary to the RNA target.
Target Amplification
Following reverse transcription of the HIV-1 target RNA and the HIV-1 QS RNA, the Thermal Cycler in the
COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer heats the reaction mixture to denature the
RNA:cDNA hybrid and to expose the specific primer target sequences. As the mixture cools, the primers
anneal to the target DNA. The thermostable Thermus specie Z05 DNA Polymerase (Z05) in the presence of
Mn2+ and excess deoxynucleotide triphosphates (dNTPs), including deoxyadenosine, deoxyguanosine,
deoxycytidine, deoxyuridine and deoxythymidine triphosphates, extends the annealed primers along the
target template to produce a double-stranded DNA molecule termed an amplicon. The COBAS® TaqMan®
Analyzer or COBAS® TaqMan® 48 Analyzer automatically repeats this process for a designated number of
cycles, with each cycle intended to double the amount of amplicon DNA. The required number of cycles is
preprogrammed into the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer. Amplification occurs
only in the region of the HIV-1 genome between the primers; the entire HIV-1 genome is not amplified.
Selective Amplification
Selective amplification of target nucleic acid from the specimen is achieved in the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test by the use of AmpErase (uracil-N-glycosylase) enzyme and
deoxyuridine triphosphate (dUTP). The AmpErase enzyme recognizes and catalyzes the destruction of DNA
strands containing deoxyuridine33, but not DNA containing deoxythymidine. Deoxyuridine is not present
in naturally occurring DNA, but is always present in amplicon due to the use of deoxyuridine triphosphate
as one of the dNTPs in the Master Mix reagent; therefore, only amplicon contains deoxyuridine.
Deoxyuridine renders contaminating amplicon susceptible to destruction by the AmpErase enzyme prior
to amplification of the target DNA. Also, any nonspecific product formed after initial activation of the Master
Mix by manganese is destroyed by the AmpErase enzyme. The AmpErase enzyme, which is included in
the Master Mix reagent, catalyzes the cleavage of deoxyuridine-containing DNA at the deoxyuridine
residues by opening the deoxyribose chain at the C1-position. When heated in the first thermal cycling
step, the amplicon DNA chain breaks at the position of the deoxyuridine, thereby rendering the DNA non-
amplifiable. The AmpErase enzyme remains inactive for a prolonged period of time once exposed to tem
peratures above 55ºC, i.e. throughout the thermal cycling steps, and therefore does not destroy target
amplicon formed after PCR.
Detection of PCR Products in a COBAS® TaqMan® Test
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test utilizes real-time34,35 PCR technology. The use of
dual-labeled fluorescent probes allows for real-time detection of PCR product accumulation by monitoring
of the emission intensity of fluorescent reporter dyes released during the amplification process. The probes
consist of HIV-1 and HIV-1 QS-specific oligonucleotide probes with a reporter dye and a quencher dye. In
the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, the HIV-1 and HIV-1 QS probes are labeled with dif
ferent fluorescent reporter dyes. When these probes are intact, the fluorescence of the reporter dye is sup
pressed by the proximity of the quencher dye due to Förster-type energy transfer effects. During PCR, the
probe hybridizes to a target sequence and is cleaved by the 5' → 3' nuclease activity of the thermostable
Z05 DNA polymerase. Once the reporter and quencher dyes are released and separated, quenching no
longer occurs, and the fluorescent activity of the reporter dye is increased. The amplification of HIV-1 RNA
and HIV-1 QS RNA are measured independently at different wavelengths. This process is repeated for a des
ignated number of cycles, each cycle effectively increasing the emission intensity of the individual reporter
dyes, permitting independent identification of HIV-1 RNA and HIV-1 QS RNA. The PCR cycle where a growth
curve starts exponential growth is related to the amount of starting material at the beginning of the PCR.
Fundamentals of COBAS® TaqMan® Test Quantitation

The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is inherently quantitative over a very wide dynamic
range since the monitoring of amplicon is performed during the exponential phase of amplification. The
higher the HIV-1 titer of a specimen, the earlier the fluorescence of the reporter dye of the HIV-1 probe rises
above the baseline fluorescence level (see Figure 1). Since the amount of HIV-1 QS RNA is constant between
all specimens, the fluorescence of the reporter dye of the HIV-1 QS probe should appear at the same cycle
for all specimens (see Figure 2). In specimens where the QS fluorescence is affected, the concentration is
adjusted accordingly. The appearance of the specific fluorescent signals is reported as a critical threshold
value (Ct). The Ct is defined as the fractional cycle number where reporter dye fluorescence exceeds a pre
determined threshold (the Assigned Fluorescence Level), and starts the exponential growth phase of this
signal (see Figure 3). A higher Ct value indicates a lower titer of initial HIV-1 target material. A 2-fold increase
in titer correlates with a decrease of 1 Ct for target HIV-1 RNA, while a 10-fold increase in titer correlates
with a decrease of 3.3 Ct.
Figure 1 shows the target growth curves for a dilution series spanning a 5-log10 range. As the concentration of
the virus increases, the growth curves shift to earlier cycles. Therefore, the leftmost growth curve corresponds
to the highest viral titer level, whereas, the rightmost growth curve corresponds to the lowest viral titer level.
Figure 1
Target Growth Curves for a Dilution Series Spanning a 5-log10 Range
9.00
8.00
7.00
6.00
Normalized Fluorescence
5.00
4.00
3.00 Highest Titer
2.00
1.00 Lowest Titer
0.00
-1.00
0 10 20 30 40 50 60
Cycle Number
Figure 2 shows the Quantitation Standard growth curves for specimens from a viral dilution series that
spans a 5-log10 range. The amount of Quantitation Standard added to each specimen is constant for
each reaction. The Ct value of the Quantitation Standard is similar regardless of the target viral titer.
Figure 2
Quantitation Standard Growth Curves for Specimens from a Viral Dilution Series
that Spans a 5-log10 Range
35.00
30.00 Lowest Titer
25.00
Normalized Fluorescence
20.00
15.00
10.00
5.00 Highest Titer
0.00
-5.00
0 10 20 30 40 50 60
Cycle Number
Figure 3 provides an example of how the fluorescence values at every cycle are normalized for each
growth curve. The critical threshold value (Ct) is calculated where the fluorescence signal crosses the
Assigned Fluorescence Level.
Figure 3
Normalization of Fluorescence Values at Every Cycle for Each Growth Curve
0.9
Normalized Fluorescence 0.8 Assigned Fluorescence Ct Value = 27.1

Level
0.7
0.6
0.5
0.4
0.3
0.2
0.1
-0.1
-0.2
19 20 21 22 23 24 25 26 27 28 29
Cycle Number
HIV-1 RNA Quantitation

The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test quantitates HIV-1 viral RNA by utilizing a second
target sequence (HIV-1 Quantitation Standard) that is added to each test specimen at a known concentra
tion. The HIV-1 QS is a non-infectious Armored RNA construct, containing fragments of HIV-1 sequences
with primer binding regions identical to those of the HIV-1 target sequence. The HIV-1 QS contains HIV-1
primer binding regions and generates an amplification product of the same length and base composition as
the HIV-1 target RNA. The detection probe binding region of the HIV-1 QS has been modified to differentiate
HIV-1 QS amplicon from HIV-1 target amplicon.
During the annealing phase of the PCR on the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48
Analyzer, the specimens are illuminated and excited by filtered light and filtered emission fluorescence
data are collected for each specimen. The readings from each specimen are then corrected for instru
mental fluctuations. These fluorescence readings are sent by the instrument to the AMPLILINK software
and stored in a database. Pre-Checks are used to determine if the HIV-1 RNA and HIV-1 QS RNA data
represent sets that are valid, and flags are generated when the data lie outside the preset limits. After
all Pre-Checks are completed and passed, the fluorescence readings are processed to generate Ct values
for the HIV-1 RNA and the HIV-1 QS RNA. The lot-specific calibration constants provided with the
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test are used to calculate the titer value for the specimens
and controls based upon the HIV-1 RNA and HIV-1 QS RNA Ct values. The COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test is standardized against the WHO 1st International Standard for HIV-1 RNA for Nucleic
Acid-Based Techniques (NAT) (NIBSC 97/656)36. Titer results are reported in copies/mL (cp/mL). The con
version factor between reported HIV-1 RNA copies/mL and HIV-1 International Units/mL has been deter
mined by Roche Molecular Systems, Inc. to be 0.6 cp/IU (1.7 IU/cp).
REAGENTS
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test HIMCAP
48 Tests
(P/N: 03542998 190)
HIV-1 CS1 1 x 48 Tests
(HIV-1 Magnetic Glass Particles Reagent Cassette) 1 x 7.0 mL
Magnetic glass particles
93% Isopropanol
Xi 93% (w/w) Isopropanol
+ Irritant
F 93% (w/w) Isopropanol
h
Highly
Flammable
(HIV-1 Lysis Reagent Cassette) 1 x 78 mL
Sodium citrate dihydrate
42.5% Guanidine thiocyanate
< 14% Polydocanol

0.9% Dithiothreitol
Xn 42.5% (w/w) Guanidine thiocyanate
+
Harmful
HIV-1 Multi-Reagent Cassette containing:
Pase 1 x 3.8 mL
(Proteinase Solution)
Tris buffer
< 0.05% EDTA
Calcium chloride
Calcium acetate
≤ 7.8% Proteinase
Glycerol
Xn ≤ 7.8% (w/w) Proteinase
+
Harmful
EB 1 x 7.0 mL
(Elution Buffer)
Tris-base buffer
0.2% Methylparaben
HIV-1 Test-Specific Reagent Cassette containing:
HIV-1 QS 1 x 3.6 mL
(HIV-1 Quantitation Standard)
Tris-HCl buffer
EDTA
< 0.005% Poly rA RNA (synthetic)
< 0.001% Armored HIV-1 RNA construct containing HIV-1 primer
binding sequences and a unique probe binding region
(non-infectious RNA in MS2 bacteriophage)
0.05% Sodium azide
6
HIV-1 MMX 1 x 2.5 mL
(HIV-1 Master Mix)
Tricine buffer
Potassium acetate
Potassium hydroxide
20% Dimethylsulfoxide
Glycerol
< 0.04% dATP, dCTP, dGTP, dUTP, dTTP
< 0.003% Upstream and downstream primers to the GAG
region of HIV-1
< 0.003% Oligonucleotide aptamer
< 0.003% Fluorescent-labeled oligonucleotide probes
specific for HIV-1 and the HIV-1 QS
< 0.05% Z05 DNA Polymerase (microbial)
< 0.1% AmpErase (uracil-N-glycosylase) enzyme (microbial)
0.09% Sodium azide
CAP/CTM Mn2+ 1 x 19.8 mL

(CAP/CTM Manganese Solution)
< 0.5% Manganese acetate
Glacial acetic acid
0.09% Sodium azide
HIV-1 H(+)C 4 x 1.0 mL

(HIV-1 High Positive Control)
< 0.001% Armored HIV-1 RNA construct containing HIV-1
sequences (non-infectious RNA in MS2 bacteriophage)
Negative Human Plasma, non-reactive by FDA licensed tests
for antibody to HCV, antibody to HIV-1/2, HIV p24 antigen
and HBsAg; HIV-1 RNA, HCV RNA and HBV DNA not detectable
by PCR methods
0.1% ProClin® 300 preservative

HIV-1 L(+)C 4 x 1.0 mL
(HIV-1 Low Positive Control)
< 0.001% Armored HIV-1 RNA construct containing HIV-1
sequences (non-infectious RNA in MS2 bacteriophage) at a mean
concentration at least 100 fold lower than the mean concentration
of Armored HIV-1 RNA in HIV-1 H(+)C
Negative Human Plasma, non-reactive by FDA licensed tests for
antibody to HCV, antibody to HIV-1/2, HIV p24 antigen and HBsAg;
HIV-1 RNA, HCV RNA and HBV DNA not detectable by PCR methods

CTM (–) C 4 x 1.0 mL
[COBAS® TaqMan® Negative Control (Human Plasma)]
Negative Human Plasma, non-reactive by FDA licensed tests for
antibody to HCV, antibody to HIV-1/2, HIV p24 antigen and HBsAg;
HIV-1 RNA, HCV RNA and HBV DNA not detectable by PCR methods

HIV-1 H(+)C Clip 1 x 4 Clips
(HIV-1 High Positive Control Barcode Clip)
HIV-1 L(+)C Clip 1 x 4 Clips
(HIV-1 Low Positive Control Barcode Clip)
HIV-1 (–) C Clip 1 x 4 Clips
(HIV-1 Negative Control Barcode Clip)
PG WR
COBAS® AmpliPrep/COBAS® TaqMan® Wash Reagent
(P/N: 03587797 190)
PG WR 1 x 5.1 L
(COBAS® AmpliPrep/COBAS® TaqMan® Wash Reagent)
Sodium citrate dihydrate
< 0.1% N-Methylisothiazolone-HCl
WARNINGS AND PRECAUTIONS

A. FOR IN VITRO DIAGNOSTIC USE.
B. This test is for use with human plasma collected in the anticoagulant EDTA.
C. Do not pipet by mouth.
D. Do not eat, drink or smoke in laboratory work areas. Wear protective disposable gloves, labora
tory coats and eye protection when handling specimens and kit reagents. Wash hands thoroughly
after handling specimens and test reagents.
E. Avoid microbial and ribonuclease contamination of reagents when removing aliquots from control vials.
F. The use of sterile disposable pipets and RNase-free pipet tips is recommended.
G. Do not pool controls from different lots or from different vials of the same lot.
H. Do not mix reagent cassettes or controls from different kits.
I. Do not allow reagent cassettes to come to ambient temperature outside the COBAS® AmpliPrep
Instrument.
J. Do not open COBAS® AmpliPrep cassettes and exchange, mix, remove or add bottles.
K. Dispose of unused reagents, waste and specimens in accordance with country, federal, state and
local regulations.
L. Do not use a kit after its expiration date.
M. Material Safety Data Sheets (MSDS) are available on request from your local Roche office.
N. Specimens and controls should be handled as if infectious using safe laboratory procedures such
as those outlined in Biosafety in Microbiological and Biomedical Laboratories37 and in the CLSI
Document M29-A38. Thoroughly clean and disinfect all work surfaces with a freshly prepared solu
tion of 0.5% sodium hypochlorite in deionized or distilled water.
NOTE: Commercial liquid household bleach typically contains sodium hypochlorite at a concen
tration of 5.25%. A 1:10 dilution of household bleach will produce a 0.5% sodium hypochlo
rite solution. Do not autoclave bleach solution.
O. CAUTION: CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C contain Human Plasma derived from human
blood. The source material has been tested by FDA licensed tests and found non-reactive for the
presence of Hepatitis B Surface Antigen (HBsAg), antibodies to HIV-1/2 and HCV, and HIV p24
Antigen. Testing of Negative Human Plasma by PCR methods showed no detectable HIV-1 RNA,
HCV RNA or HBV DNA. No known test methods can offer complete assurance that products
derived from human blood will not transmit infectious agents. Therefore, all human sourced mate
rial should be considered potentially infectious. CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C should
be handled as if infectious using safe laboratory procedures such as those outlined in Biosafety in
Microbiological and Biomedical Laboratories37 and in the CLSI Document M29-A38. Thoroughly
clean and disinfect all work surfaces (for instrument work surfaces see COBAS® AmpliPrep
Instrument Manual for use with the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer
and the AMPLILINK Software, Version 3.1.x Series) with a freshly prepared solution of 0.5% sodium
hypochlorite in deionized or distilled water.
P. HIV-1 QS, CAP/CTM Mn2+ and HIV-1 MMX contain sodium azide. Sodium azide may react with
lead and copper plumbing to form highly explosive metal azides. While disposing of sodium azide-
containing solutions down laboratory sinks, flush the drains with a large volume of water to pre
vent azide buildup.
Q. Wear eye protection, laboratory coats and disposable gloves when handling any reagent. Avoid con
tact of these materials with the skin, eyes or mucous membranes. If contact does occur, immedi
ately wash with large amounts of water. Burns can occur if left untreated. If spills of these reagents
occur, dilute with water before wiping dry.
R. Do not allow HIV-1 CS2 and liquid waste from the COBAS® AmpliPrep Instrument, which contain
guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. These mixtures can pro
duce a highly toxic gas.
S. When disposing of used COBAS® AmpliPrep Sample Processing Units (SPUs), which contain guani
dine thiocyanate, avoid any contact with sodium hypochlorite (bleach) solution. These mixtures can
produce a highly toxic gas.
STORAGE AND HANDLING REQUIREMENTS

A. Do not freeze reagents or controls.
8
B. Store HIV-1 CS1, HIV-1 CS2, HIV-1 CS3 and HIV-1 CS4 at 2-8ºC. Unused, these reagents are
stable until the expiration date indicated. Once used, these reagents are stable for 28 days at
2-8°C or until the expiration date, whichever comes first. HIV-1 CS1, HIV-1 CS2, HIV-1 CS3 and
HIV-1 CS4 can be used for a maximum of 4 instrument cycles, up to a maximum of 64 hours cumu
lative on board the COBAS® AmpliPrep Instrument. Reagents must be stored at 2-8°C between
instrument cycles.
C. S
tore HIV-1 H(+)C, HIV-1 L(+)C and CTM (–) C at 2-8ºC. The controls are stable until the expira
tion date indicated. Once opened, any unused portion must be discarded.
D. Store Barcode clips [HIV-1 H(+)C Clip, HIV-1 L(+)C Clip and HIV-1 (–) C Clip] at 2-30°C.
E. Store PG WR at 2-30°C. PG WR is stable until the expiration date indicated. Once opened, this
reagent is stable for 28 days at 2-30°C or until the expiration date, whichever comes first.
MATERIALS PROVIDED
A. COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test HIMCAP
(P/N: 03542998 190)
HIV-1 CS1
(HIV-1 Magnetic Glass Particles Reagent Cassette)
HIV-1 CS2
(HIV-1 Lysis Reagent Cassette)
HIV-1 CS3
(HIV-1 Multi-Reagent Cassette)
HIV-1 CS4
(HIV-1 Test-Specific Reagent Cassette)
HIV-1 H(+)C
(HIV-1 High Positive Control)
HIV-1 L(+)C
(HIV-1 Low Positive Control)
CTM (–) C
[COBAS® TaqMan® Negative Control (Human Plasma)]
HIV-1 H(+)C Clip
(HIV-1 High Positive Control Barcode Clip)
HIV-1 L(+)C Clip
(HIV-1 Low Positive Control Barcode Clip)
HIV-1 (–) C Clip
(HIV-1 Negative Control Barcode Clip)
B. COBAS® AmpliPrep/COBAS® TaqMan® Wash Reagent PG WR
(P/N: 03587797 190)
PG WR
(COBAS® AmpliPrep/COBAS® TaqMan® Wash Reagent)
MATERIALS REQUIRED BUT NOT PROVIDED

Instrumentation and Software
• COBAS® AmpliPrep Instrument
• COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer
• Optional: Docking Station
• AMPLILINK Software, Version 3.1.x Series
• Data Station for the AMPLILINK software, with printer
• COBAS® AmpliPrep Instrument Manual for use with the COBAS® TaqMan® Analyzer or
COBAS® TaqMan® 48 Analyzer and the AMPLILINK Software, Version 3.1.x Series
• COBAS® TaqMan® Analyzer (plus optional Docking Station) Instrument Manual for use with
AMPLILINK Software, Version 3.1.x Series
• COBAS® TaqMan® 48 Analyzer Instrument Manual for use with AMPLILINK Software, Version
3.1.x Series
• AMPLILINK Software Version 3.1.x Series Application Manual for use with the COBAS®
AmpliPrep Instrument, COBAS® TaqMan® Analyzer, and COBAS® TaqMan® 48 Analyzer
• COBAS® TaqMan® Analyzer HIV-1 PCR TEST FILE CD ROM

• COBAS® TaqMan® 48 Analyzer HIV-1 PCR TEST FILE CD ROM
Disposables
• Sample processing units: SPUs (P/N: 03755525001)
• Sample input tubes (S-tubes) with barcode clips (P/N: 03137040001)
• Racks of K-tips (P/N: 03287343001)
• K-tube Box of 12 x 96 (P/N: 03137082001)
OTHER MATERIALS REQUIRED BUT NOT PROVIDED
• Sample Rack (SK 24 rack) (P/N: 28122172001)
• Reagent Rack (P/N: 28122199001)
• SPU rack (P/N: 28122806001)
• K-tube capper, motorized (P/N: 03516539001)
• K-tube capper (P/N: 03339874001)
• K-carrier (P/N: 28150397001)
• K-carrier Transporter (P/N: 03517519001)
• K-carrier rack (P/N: 03286436001)
• Pipettors with aerosol barrier or positive displacement RNase-free tips (capacity 1000 µL)*
• Disposable gloves, powderless
• Vortex mixer
* Pipettors should be accurate within 3% of stated volume. Aerosol barrier or positive displacement
RNase-free tips must be used where specified to prevent specimen and amplicon cross-contamination.
SPECIMEN COLLECTION, TRANSPORT AND STORAGE
NOTE: Handle all specimens and controls as if they are capable of transmitting infectious agents.
A. Specimen Collection
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is for use with plasma specimens. Blood should
be collected in sterile tubes using EDTA (lavender top) as the anticoagulant.
Store whole blood at 2-25°C for no longer than 6 hours. Separate plasma from whole blood within 6 hours
of collection by centrifugation at 800-1600 x g for 20 minutes at room temperature. Transfer plasma to a
sterile polypropylene tube. Figures 4 and 5 show the data from specimen collection studies. These studies
were performed using the COBAS® TaqMan® HIV-1 Test for use with the High Pure System (HPS),
P/N: 03501752 190 and 03502295 001).
Figure 4
HIV-1 Stability in Whole Blood with EDTA Anticoagulant
8.00
7.00
6.00
Average Log Titer
5.00
4.00
3.00
2.00
1.00
0 hr 2 hrs - 28±2˚C 6 hrs - 28±2˚C 6 hrs - 2-8˚C
Test Condition
10
B. Specimen Transport
Transportation of whole blood or plasma must comply with country, federal, state and local regulations for
the transport of etiologic agents39. Whole blood must be transported at 2-25°C and centrifuged within 6
hours of collection. Plasma may be stored at room temperature for up to 1 day, at 2-8°C for up to 5 days
or frozen at -20°C to -80°C for longer storage. Figure 5 shows the stability for HIV-1 in EDTA plasma.
C. Specimen Storage
Plasma specimens may be stored at room temperature for up to 1 day, at 2-8°C for up to 5 days or frozen
at -20°C to -80°C. It is recommended that specimens be stored in 1100-1200 µL aliquots in sterile, 2.0
mL polypropylene screw-cap tubes (such as Sarstedt 72.694.006). Plasma specimens may be frozen and
thawed up to five times without a loss of HIV-1 RNA. Figure 6 shows the data from a freeze/thaw study
(study was performed using COBAS® TaqMan® HIV-1 Test for use with the High Pure System (HPS), P/N:
03501752 190 and 03502295 001).
Figure 5
HIV-1 Stability in EDTA-Plasma
8.00
7.00
6.00
Average Log Titer
5.00
4.00
3.00
2.00
1.00
0hr 2hrs - 28±2˚C 24hrs - 28±2˚C 24hrs - 2-8˚C 72hrs - 2-8˚C 120hrs - 2-8˚C
Test Condition
Figure 6
HIV-1 Results after up to Five Freeze/Thaw Cycles
8.00
7.00
6.00
Average Log Titer
5.00
4.00
3.00
2.00
1.00
0 1 2 3 4 5
Number of Freeze/Thaw Cycles
11
INSTRUCTIONS FOR USE

NOTE: Refer to the following for detailed operating instructions: (a) the COBAS® AmpliPrep
Instrument Manual for use with the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48
Analyzer and the AMPLILINK Software, Version 3.1.x Series; and either (b) the COBAS®
TaqMan® Analyzer (plus optional Docking Station) Instrument Manual for use with
AMPLILINK Software, Version 3.1.x Series or (c) the COBAS® TaqMan® 48 Analyzer
Instrument Manual for use with AMPLILINK Software, Version 3.1.x Series.
Batch Size:
Each kit contains reagents sufficient for 48 tests, which may be performed in batches of 12 to 24 tests.
At least one replicate each of CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C must be included in each batch
(see "Quality Control" section).
Workflow:
The COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer run must be started within 120
minutes following completion of specimen and control preparation of a specific batch.
NOTE: If this time limit is exceeded, processed specimens and controls must be discarded.
(Processing time for one specimen on the COBAS® AmpliPrep Instrument is 216 seconds.
The COBAS® AmpliPrep Instrument can process three racks of 24 specimens (n = 72) in
approximately 5 hours. The amplification and detection cycle takes 3 hours, 5 minutes on
both the COBAS® TaqMan® Analyzer and COBAS® TaqMan® 48 Analyzer. Completion of the
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test takes approximately 8 hours 10 minutes
and 7 hours 35 minutes for sample processing and result generation, using the CTM 48 and
CTM 96 workflows, respectively).
NOTE: DO NOT FREEZE or STORE processed specimens and controls at 2-8°C.
Specimen and Control Preparation
NOTE: If using frozen specimens, place the specimens at room temperature until completely
thawed and vortex for 3-5 seconds before use. Controls should be removed from 2-8°C
storage and equilibrated to ambient temperature before use.
COBAS® AmpliPrep Instrument Set-up
Part A. Maintenance and Priming
A1. The COBAS® AmpliPrep Instrument is ready for operation in stand-by mode.
A2. Turn the Data Station for the AMPLILINK software ON. Prepare the Data Station as follows:
a. Log onto Windows® XP.
b. Double click the AMPLILINK software icon.
c. Log onto AMPLILINK software by entering the assigned User ID and password.
A3. Check the supply of PG WR using the Status Screen and replace if necessary.
A4. Perform all Maintenance that is listed in the Due Tab, as outlined in the COBAS® AmpliPrep
and the AMPLILINK Software, Version 3.1.x Series. The COBAS® AmpliPrep Instrument will auto
matically prime the system.
12
Part B. Loading of Reagent Cassettes

NOTE: All reagent cassettes should be removed from 2-8°C storage, immediately loaded onto the
COBAS® AmpliPrep Instrument and allowed to equilibrate to ambient temperature on the
instrument for at least 30 minutes before the first specimen is to be processed. Do not let
reagent cassettes come to ambient temperature outside the instrument.
B1. Place HIV-1 CS1 onto a reagent rack. Place HIV-1 CS2, HIV-1 CS3 and HIV-1 CS4 onto a separate
reagent rack.
B2. Load the reagent rack containing HIV-1 CS1 onto rack position A of the COBAS® AmpliPrep Instrument
as described in the COBAS® AmpliPrep Instrument Manual for use with the COBAS® TaqMan® Analyzer
or COBAS® TaqMan® 48 Analyzer and the AMPLILINK Software, Version 3.1.x Series.
B3. Load the reagent rack containing HIV-1 CS2, HIV-1 CS3 and HIV-1 CS4 onto rack position B, C,
D or E of the COBAS® AmpliPrep Instrument as described in the COBAS® AmpliPrep Instrument
Manual for use with the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer and the
AMPLILINK Software, Version 3.1.x Series (see also Table 1 for additional information).
Part C. Loading of Disposables
NOTE: Determine the number of COBAS® AmpliPrep reagent cassettes, Sample Processing Units
(SPUs), Input Sample tubes (S-tubes), K-tips and K-tubes needed. One SPU, one Input S-
tube, one K-tip and one K-tube are needed for each specimen or control.
Multiple configurations for use of the COBAS® AmpliPrep Instrument with the COBAS® TaqMan®
Analyzer or COBAS® TaqMan® 48 Analyzer are possible. For reference, see Table 1 below. Depending
on the configuration used, load the appropriate number of reagent cassette racks, sample racks with
Input S-tubes, SPU racks, K-tip racks, K-tube racks and K-carriers on K-carrier racks onto the respec
tive rack positions of the COBAS® AmpliPrep Instrument as described in the COBAS® AmpliPrep
Instrument Manual for use with the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer and
the AMPLILINK Software, Version 3.1.x Series (also see Table 1 for additional information).
C1. Place the SPUs in the SPU rack(s) and load the rack(s) onto rack position J, K or L of the COBAS®
AmpliPrep Instrument as described in the COBAS® AmpliPrep Instrument Manual for use with the
COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer and the AMPLILINK Software,
Version 3.1.x Series.
C2. Depending on the configuration used, load full K-tube rack(s) onto rack position M, N, O or P of the
COBAS® AmpliPrep Instrument as described in the COBAS® AmpliPrep Instrument Manual for use with
the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer and the AMPLILINK Software,
Version 3.1.x Series.
C3. Load full K-tip rack(s) onto rack position M, N, O or P of the COBAS® AmpliPrep Instrument as
described in the COBAS® AmpliPrep Instrument Manual for use with the COBAS® TaqMan®
Analyzer or COBAS® TaqMan® 48 Analyzer and the AMPLILINK Software, Version 3.1.x Series.
C4. For configurations 3 to 5 using the COBAS® TaqMan® 48 Analyzer, load K-carriers on K-carrier
rack(s) onto rack position M, N, O or P of the COBAS® AmpliPrep Instrument as described in the
COBAS® AmpliPrep Instrument Manual for use with the COBAS® TaqMan® Analyzer or COBAS®
TaqMan® 48 Analyzer and the AMPLILINK Software, Version 3.1.x Series.
13
Table 1
Possible Configurations for using COBAS® AmpliPrep Instrument with
COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer
Transfer mode to Position on

COBAS® TaqMan® COBAS®
Configuration Racks, carriers and disposables
Analyzer or COBAS® AmpliPrep
TaqMan® 48 Analyzer Instrument
K-tubes in full K-tube racks M-P
COBAS® K-tips in full K-tips racks M-P
AmpliPrep Input S-tubes containing F-H
Instrument plus Automated transfer specimens and controls on
1. sample racks
Docking Station of K-carrier
plus COBAS® SPUs in SPU racks J-L
TaqMan® Analyzer CS1 on Cassette rack A
CS2, CS3, CS4 on Cassette rack B-E
K-tubes in full K-tube racks M-P
K-tips in full K-tips racks M-P
Input S-tubes on sample racks F-H
COBAS® Manual transfer of SPUs in SPU racks J-L
AmpliPrep K-tubes via sample
2 Instrument plus rack(s) onto CS1 on Cassette rack A
COBAS® TaqMan® COBAS® TaqMan® CS2, CS3, CS4 on Cassette rack B-E
Analyzer Analyzer After specimen processing is
finished:
K-tubes on sample racks (ready for Same as above
manual transfer) (F-H)
K-tubes on sample racks F-H
K-tips in full K-tips racks M-P
Input S-tubes on sample racks F-H
COBAS® Manual transfer SPUs in SPU racks J-L
3. AmpliPrep of K-carrier via
CS1 on Cassette rack A
Instrument plus K-carrier rack(s)
& CS2, CS3, CS4 on Cassette rack B-E
1-2 COBAS® onto COBAS®
4. TaqMan® 48 TaqMan® 48 Empty barcoded K-carrier on M-P
Analyzer(s) Analyzer K-carrier rack
After specimen processing is
finished:
K-tubes in K-carrier on K-carrier rack Same as above (M-P)
Manual transfer of
COBAS® K-tubes on sample
AmpliPrep rack to COBAS®
Instrument plus TaqMan® Analyzer. Same as
5. COBAS® TaqMan® Manual transfer Same as configurations 2 and 3 configurations
Analyzer plus of K-carrier via 2 and 3
COBAS® TaqMan® K-carrier rack to
48 Analyzer COBAS® TaqMan®
48 Analyzer
14
Part D. Ordering and Loading of Specimens

D1. Prepare sample racks as follows: Attach a barcode label clip to each sample rack position where
a specimen (S-tube) is to be placed. Attach one of the specific barcode label clips for the controls
[CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C] to each sample rack position where the controls
(S-tube) are to be placed. The barcode label clips for controls must have the same control lot
number as the lot number on the control vials in the kit. Take care in assigning the correct control
to the position with the appropriate control barcode clip. Place one Input S-tube into each posi
tion containing a barcode label clip.
D2. Using the AMPLILINK software, create specimen orders for each specimen and control in the Orders
window Sample folder. The Test file name in the Orders window will be HIMAPU96 or HIMAPU48.
Select the appropriate test file and complete by saving.
D3. Assign specimen and control orders to sample rack positions in the Orders window Sample Rack
folder. The sample rack number must be entered for the rack prepared in Step D1.
D4. Print the Sample Rack Order report to use as a worksheet.
D5. Prepare specimen and control racks in the designated area for specimen and control addition as
follows: Vortex each specimen and control [CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C] for 3 to 5
seconds. Avoid contaminating gloves when manipulating the specimens and controls.
D6. Transfer 1000 to 1050 µL of each specimen and control [CTM (–) C, HIV-1 L(+)C and HIV-1 H(+)C]
to the appropriate barcode labeled Input S-tube using a micropipettor with an aerosol barrier or
positive displacement RNase-free tip. Avoid transferring particulates and/or fibrin clots from
the original specimen to the Input S-tube. Specimens and controls should be transferred to tube
positions as assigned and recorded on the worksheet in step D4. The barcode label clips for con
trols must have the same control lot number as the lot number on the control vials in the kit. Assign
the correct control to the position with the appropriate control barcode clip. Avoid contaminating
the upper part of the S-tubes with specimens or controls.
D7. For configurations 1 and 2 using the COBAS® TaqMan® Analyzer, load the sample rack(s) filled
with Input S-tubes onto rack positions F, G or H of the COBAS® AmpliPrep Instrument.
D8. For configurations 3 to 5 using the COBAS® TaqMan® 48 Analyzer, load sample rack(s) with Input
S-tubes and K-tubes (one for each Input S-tube, loaded in the correct position adjacent to Input
S-tubes) onto rack position F, G or H of the COBAS® AmpliPrep Instrument as described in the
COBAS® AmpliPrep Instrument Manual for use with the COBAS® TaqMan® Analyzer or COBAS®
TaqMan® 48 Analyzer and the AMPLILINK Software, Version 3.1.x Series.
Part E. Start of COBAS® AmpliPrep Instrument Run
E1. Start the COBAS® AmpliPrep Instrument using the AMPLILINK software as described in the
AMPLILINK Software Version 3.1.x Series Application Manual for use with the COBAS® AmpliPrep
Instrument, COBAS® TaqMan® Analyzer, and COBAS® TaqMan® 48 Analyzer.
Part F. End of COBAS® AmpliPrep Instrument Run and Transfer to COBAS® TaqMan® Analyzer or
COBAS® TaqMan® 48 Analyzer (only for configurations 2-5)
F1. Check for flags or error messages in the system screen as described in (a) the COBAS® AmpliPrep
and the AMPLILINK Software, Version 3.1.x Series and (b) the AMPLILINK Software Version 3.1
Series Application Manual for use with the COBAS® AmpliPrep Instrument, COBAS® TaqMan®
Analyzer, and COBAS® TaqMan® 48 Analyzer.
F2. Remove processed specimens and controls from the COBAS® AmpliPrep Instrument on either
sample racks (for COBAS® TaqMan® Analyzer without docking station) or K-carrier racks (for
COBAS® TaqMan® 48 Analyzer), depending on the configuration (for further details see Part G).
F3. Remove waste from COBAS® AmpliPrep Instrument.
NOTE: All processed specimens and controls should not be exposed to light after completion of
specimen and control preparation.
15
Amplification and Detection

COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer Set-up
The COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer run must be started within 120 min
utes following completion of specimen and control preparation. If this time limit is exceeded, the
processed specimens and controls must be discarded.
NOTE: DO NOT FREEZE or STORE processed specimens and controls at 2-8°C.
For a detailed description of the possible configurations, refer to (a) the COBAS® TaqMan® Analyzer (plus
optional Docking Station) Instrument Manual for use with AMPLILINK Software, Version 3.1.x Series; (b)
the COBAS® TaqMan® 48 Analyzer Instrument Manual for use with AMPLILINK Software, Version 3.1.x
Series and Part C of this Package Insert.
Part G. Loading Processed Specimens
G1. Depending on the instrument configuration, perform the appropriate steps to transfer the K-tubes
to the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer:
Configuration 1: Automated transfer of K-carrier via docking station to COBAS®
TaqMan® Analyzer. Manual intervention is unnecessary.
Configuration 2 and 5: Manual transfer of K-tubes in sample rack(s) to COBAS® TaqMan®

Analyzer
Configuration 3, 4 and 5: Manual transfer of K-carrier on K-carrier rack(s) to the COBAS®

TaqMan® 48 Analyzer. Manual transfer of K-carriers into COBAS®
TaqMan® 48 Analyzer using the K-carrier Transporter.
Part H. Start of COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer Run
H1. Start the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer by one of the options
below depending on the instrument configuration used:
Configuration 1: No intervention necessary.
Configuration 2 and 5: Automatic start of the COBAS® TaqMan® Analyzer after insertion of sample
rack(s).
Configuration 3, 4 and 5: Fill K-carrier with empty K-tubes if there are fewer than 6 K-tubes on the
K-carrier. Filling is guided by the AMPLILINK software. Open thermal
cycler cover, load K-carrier into thermal cycler and close lid. Start the
COBAS® TaqMan® 48 Analyzer run.
Part I. End of COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer Run
I1. At the completion of the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer run, print
Results Report. Check for flags or error messages in the Result Report as described in (a) the
COBAS® TaqMan® Analyzer (plus optional Docking Station) Instrument Manual for use with
AMPLILINK Software, Version 3.1.x Series or (b) the COBAS® TaqMan® 48 Analyzer Instrument
Manual for use with AMPLILINK Software, Version 3.1.x Series and (c) the AMPLILINK Software
Version 3.1.x Series Application Manual for use with the COBAS® AmpliPrep Instrument, COBAS®
TaqMan® Analyzer, and COBAS® TaqMan® 48 Analyzer. Specimens with flags and comments are
interpreted as described in the Results section. After acceptance, store data in archive.
I2. Remove used K-tubes from the COBAS® TaqMan® 48 Analyzer. If using the COBAS® TaqMan® 48
Analyzer, tubes are transferred to a waste container, which should be emptied as described in the
COBAS® TaqMan® Analyzer Instrument Manual.
NOTE: Caution! K-carrier may be hot after cycling.
16
RESULTS
The COBAS® TaqMan® Analyzer or the COBAS® TaqMan® 48 Analyzer automatically determines the
HIV-1 RNA concentration for the specimens and controls. The HIV-1 RNA concentration is expressed in
copies (cp)/mL. The conversion factor between HIV-1 RNA copies/mL and HIV-1 International Units
(IU)/mL is 0.6 cp/IU, using the WHO 1st International Standard for HIV-1 RNA for Nucleic Acid-Based
Techniques (NAT) (NIBSC 97/656).
AMPLILINK Software:
• Determines the Cycle Threshold value (Ct) for the HIV-1 RNA and the HIV-1 QS RNA.
• Determines the HIV-1 RNA concentration based upon the Ct values for the HIV-1 RNA and
HIV-1 QS RNA and the lot-specific calibration coefficients provided on the cassette barcodes.
• Determines that the calculated cp/mL for HIV-1 L(+)C and HIV-1 H(+)C fall within the assigned ranges.
Batch Validation
Check AMPLILINK software results window or printout for flags and comments to ensure that the
batch is valid.
NOTE: For instructions on printing results and for interpreting flags and comments, please refer
to the following: (a) the AMPLILINK Software Version 3.1.x Series Application Manual for
use with the COBAS® AmpliPrep Instrument, COBAS® TaqMan® Analyzer, and COBAS®
TaqMan® 48 Analyzer or (b) the COBAS® AmpliPrep Instrument Manual for use with the
COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer and the AMPLILINK
Software, Version 3.1.x Series and (c) the COBAS® TaqMan® Analyzer (plus optional
Docking Station) Instrument Manual for use with AMPLILINK Software, Version 3.1.x Series
or (d) the COBAS® TaqMan® 48 Analyzer Instrument Manual for use with AMPLILINK
Software, Version 3.1.x Series.
For control orders, a check is made to determine if the cp/mL value for the control is within its spec
ified range. If the cp/mL value for the control lies outside of its range, a FLAG is generated to show
the control has failed.
The batch is valid if no flags appear for any of the controls [HIV-1 H(+)C, HIV-1 L(+)C, CTM (–) C].
The following results are obtained for a valid batch:
Control Result Interpretation

Negative Control Target Not Detected Control within range
Low Positive Control A numeric titer, X.XXE+XX cp/mL Control within range
High Positive Control A numeric titer, X.XXE+XX cp/mL Control within range
The batch is not valid if any of the following flags appear for the HIV-1 Controls:
Negative Control:
Flag Result Interpretation
An invalid result or a "valid"
__N_NC_INVALID Invalid result that was not negative
for HIV-1 target
17
HIV-1 Low Positive Control:

__L_LPCINVALID < 4.80E+01 cp/mL Control below range
__L_LPCINVALID Target Not Detected Control below range
__L_LPCINVALID A numeric titer, X.XXE+XX cp/mL Control out of range
__L_LPCINVALID > 1.00E+07 cp/mL Control above range
__L_LPCINVALID Invalid An invalid result
HIV-1 High Positive Control:

__H_HPCINVALID < 4.80E+01 cp/mL Control below range
__H_HPCINVALID Target Not Detected Control below range
__H_HPCINVALID A numeric titer, X.XXE+XX cp/mL Control out of range
__H_HPCINVALID > 1.00E+07 cp/mL Control above range
__H_HPCINVALID Invalid An invalid result
If the batch is invalid, repeat the entire batch including specimen and control preparation, amplification
and detection.
Interpretation of Results:
For a valid batch, check each individual specimen for flags or comments on the result printout. Interpret
the results as follows:
⇒ A valid batch may include both valid and invalid specimen results depending on whether flags
and/or comments are obtained for the individual specimens.
Specimen results are interpreted as follows:
Titer Result Interpretation
Target Not Detected Ct value for HIV-1 above the limit for the assay or no Ct value for HIV-1
obtained. Report results as "HIV-1 RNA not detected".
< 4.80E+01 cp/mL Calculated cp/mL are below the Limit of Detection of the assay. Report
results as "HIV-1 RNA detected, less than 48 HIV-1 RNA cp/mL".
≥ 4.80E+01 cp/mL and Calculated results greater than or equal to 48 cp/mL and less than or
≤ 1.00E+07 cp/mL equal to 1.00E+07 cp/mL are within the Linear Range of the assay.
> 1.00E+07 cp/mL Calculated cp/mL are above the range of the assay. Report results as
"greater than 1.00E+07 HIV-1 RNA cp/mL". If quantitative results are
desired, the original specimen should be diluted with HIV-1-negative
human EDTA-plasma and the test repeated. Multiply the reported result
by the dilution factor.
NOTE: Specimens above the range of the assay may also produce an Invalid result with a flag
"QS_INVALID". If quantitative results are desired, the original specimen should be diluted
with HIV-1-negative human EDTA-plasma and the test repeated. Multiply the reported
result by the dilution factor.
18
QUALITY CONTROL
One replicate each of the COBAS® TaqMan® Negative Control, the HIV-1 Low Positive Control and the
HIV-1 High Positive Control must be included in each test batch. The batch is valid if no flags appear for any
of the controls [HIV-1 H(+)C, HIV-1 L(+)C and CTM (–) C].
There are no requirements regarding the position of the controls on the sample rack.
Check the batch printout for flags and comments to ensure that the batch is valid. Refer to the following
manuals for detailed information on printing results and interpreting comments: (a) the AMPLILINK Software
Version 3.1.x Series Application Manual for use with the COBAS® AmpliPrep Instrument, COBAS® TaqMan®
Analyzer, and COBAS® TaqMan® 48 Analyzer and either (b) the COBAS® TaqMan® Analyzer (plus optional
Docking Station) Instrument Manual for use with AMPLILINK Software, Version 3.1.x Series or (c) the
COBAS® TaqMan® 48 Analyzer Instrument Manual for use with AMPLILINK Software, Version 3.1.x Series.
Negative Control
The CTM (–) C must yield a "Target Not Detected" result. If the CTM (–) C is flagged as invalid, then the entire
batch is invalid. Repeat the entire process (specimen and control preparation, amplification and detection). If
CTM (–) C is consistently invalid in multiple batches, contact your local Roche office for technical assistance.
Positive Controls
The assigned range for HIV-1 L(+)C and HIV-1 H(+)C is specific for each lot of reagents, and is provided
on the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test reagent cassette barcodes.
The HIV-1 RNA cp/mL for HIV-1 L(+)C and HIV-1 H(+)C should fall within their assigned ranges. If one or both of
the positive controls are flagged as invalid, then the entire batch is invalid. Repeat the entire process (specimen and
control preparation, amplification and detection). If the HIV-1 RNA titer of one or both of the positive controls is con
sistently outside the assigned ranges in multiple batches, contact your local Roche office for technical assistance.
PROCEDURAL PRECAUTIONS
1. As with any test procedure, good laboratory technique is essential to the proper performance of this
assay.
PROCEDURAL LIMITATIONS
1. This test has been validated for use with only human plasma collected in EDTA anticoagulant. Testing
of other specimen types may result in inaccurate results.
2. The performance of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test has neither been evalu
ated with specimens containing HIV-1 groups O and N, nor with specimens containing HIV-2.
3. Reliable results are dependent on adequate specimen collection, transport, storage and processing
procedures.
4. The presence of AmpErase enzyme in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Master Mix
reduces the risk of amplicon contamination. However, contamination from HIV-1 positive controls and
clinical specimens can be avoided only by good laboratory practices and careful adherence to the
procedures specified in this Package Insert.
5. Use of this product should be limited to personnel trained in the techniques of PCR.
6. This product can only be used with the COBAS® AmpliPrep Instrument and the COBAS® TaqMan®
Analyzer or COBAS® TaqMan® 48 Analyzer.
19
INTERFERING SUBSTANCES
Elevated levels of triglycerides, bilirubin, albumin, hemoglobin and human DNA in specimens as well as the
presence of autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)
and Antinuclear Antibody (ANA) have been shown not to interfere with the quantitation of HIV-1 RNA or impact
the specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test.
The following drug compounds tested at the Peak Plasma Level (Cmax) and at 3 times the Cmax have been
shown not to interfere with the quantitation of HIV-1 RNA or impact the specificity of the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test with the exception of Nevirapine, for which absence of interference
has only been shown at the Peak Plasma Level (Cmax):
Nucleotide DNA Polymerase Inhibitors Nucleoside Reverse Transcriptase and DNA

Tenofovir Polymerase Inhibitors
Adefovir dipivoxil Lamivudine
Zidovudine
Stavudine
Abacavir
Didanosine
HIV Protease Inhibitors Non-nucleoside HIV Reverse

Indinavir Transcriptase Inhibitors
Saquinavir Nevirapine
Ritonavir Efavirenz
Nelfinavir
Amprenavir
Lopinavir/Ritonavir HIV Fusion Inhibitor
Enfuvirtide
Immune Modulators Antidepressants

Interferon alpha-2a Paroxetine HCl
Interferon alpha-2b Fluoxetine
Peginterferon alpha-2a Sertraline
Peginterferon alpha-2a + Ribavirin
Interferon alpha-2b + Ribavirin
Compounds for the Treatment of Herpes
Nucleoside Inhibitors Viruses
Ribavirin Ganciclovir
Valganciclovir
Acyclovir
20
NON-CLINICAL PERFORMANCE EVALUATION

A. Limit of Detection
The limit of detection of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was determined by
analysis of three independent dilution series of a HIV-1 Secondary Standard (prepared from the HIV-1B
strain 8E5 LAV in HIV-1-negative human EDTA plasma). The concentration of the HIV-1 Secondary
Standard is traceable to the WHO 1st International Standard for HIV-1 RNA for Nucleic Acid-Based
Techniques (NAT) (NIBSC 97/656). A total of 108 replicates per concentration level were tested.
The concentration of HIV-1 RNA in EDTA plasma that can be detected with a positivity rate of greater than
95% as determined by probit analysis is 48 cp/mL. The study was performed for three lots of COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test reagents and the combined results are shown in Table 2.
Table 2
Limit of Detection of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
determined with HIV-1B Secondary Standard in EDTA plasma
Level HIV-1B Input Conc. Total Number of Number of

Hit Rate
No. (copies/mL) Replicates Tested Positives
1 100 108 108 100%
2 75 108 108 100%
3 50 108 107 99%
4 40 108 99 92%
5 30 108 98 91%
6 20 108 81 75%
7 10 108 55 51%
B. Precision
Precision and linearity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test were determined by
analysis of serial dilutions prepared from a highly concentrated cell culture stock of the HIV-1B in HIV-1
negative human EDTA plasma. The concentration assignment of the HIV-1B linearity panel was performed
by a method that ensures traceability to the WHO 1st International Standard for HIV-1 RNA for Nucleic
Acid-Based Techniques (NAT) (NIBSC 97/656).
Within-Run, Run-to-Run and Total Precision were evaluated in accordance with the methods defined in
the CLSI Guideline EP5-A, "Evaluation of Precision Performance of Clinical Chemistry Devices".41 A run,
consisting of 5 dilution levels and 7 replicates at each level, was performed daily for 15 days. Each sample
was carried through the entire COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test procedure, including
specimen preparation, amplification and detection using different systems operated by multiple users.
Therefore, the precision reported here represents all aspects of the test procedure. The study was per
formed for three lots of COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test reagents, and the results are
shown in Table 3.
Table 3
Total Precision for three lots of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
Lot 1 Lot 2 Lot 3

Nominal
Log10 of Total Total Total
HIV-1 Conc.
Nominal Total CV precision as Total CV precision as Total CV precision as
Levels
Conc. [%] SD [%] SD [%] SD
[cp/mL]
[log10] [log10] [log10]
1.0E+02 2.000 39.5 0.18 41.4 0.18 41.8 0.18
4.3E+03 3.634 24.5 0.11 29.3 0.13 23.1 0.10
4.3E+04 4.634 20.0 0.09 20.6 0.09 16.9 0.08
4.3E+05 5.634 22.4 0.10 20.0 0.09 22.8 0.10
2.2E+06 6.333 24.0 0.10 23.5 0.10 24.7 0.10
21
C. Linear Range
As shown in Figure 7, the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was found to give a linear
response from 48 HIV-1 RNA cp/mL to 10,000,000 HIV-1 RNA cp/mL applying the accuracy acceptance
criterion of ± 0.3 log10 from the nominal input concentration. The study was performed using one lot of
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test reagents, with 103 – 105 replicates per level.
Figure 7
Linear range of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
COBAS® AmpliPrep/COBAS® TaqMan®

9
8 y = 1.0086x - 0.0555
HIV-1 Test Mean log10 Result
2
7 R = 0.99
6
0
0 1 2 3 4 5 6 7 8
Log 10 Nominal HIV-1 RNA Input Concentration (cp/mL)
D. Inclusivity
Eight subtype categories have been proposed for HIV-1 group M based on nucleotide divergence. These
subtypes are designated with capital alphabetical letters from A through H40.
Similar Subtype Quantitation
The performance of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test on HIV-1 subtypes was eval
uated by analysis of cell culture stock material of representatives of each HIV-1 group M subtype A
through H. The assignment of nominal concentrations of the cell culture stock solutions was performed
by the COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 assay method (Figure 8).
Based on the determined stock concentrations, the HIV-1 target concentrations of 2.0E+02, 1.9 - 3.3E+04
and 1.0E+05 - 1.0E+06 cp/mL were prepared for each HIV-1 subtype by exact dilution of the cell culture
stock solution in EDTA plasma. Afterwards the concentrations were determined by the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test in n=7 replicates per level of each subtype using one reagent
lot. Results were compared to the input concentrations as determined by the reference method.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test gave equivalent results for all tested representa
tives of the HIV-1 group M subtypes (see Figure 8). Mean observed log10 concentration results were within
± 0.3 log10 of the respective reference method input concentration.
22
Figure 8
Performance of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test on HIV-1 group M
Subtypes A through H compared against the reference method
COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5
COBAS® AmpliPrep/COBAS® AMPLICOR®HIV-1 MONITOR Test, v1.5

6.5
COBAS® AmpliPrep / COBAS®TaqMan® HIV-1 Test
5.5
Mean Log10 Concentration
4.5
3.5
2.5
1.5
A B C D E F G H
HIV-1 Group M Subtype
Subtype Limit of Detection

Parent solutions containing HIV-1 cell culture material representing HIV-1 subtypes A to H have been obtained
as frozen stocks from German National Reference Centre for Retrovirology at University Erlangen-Nuremberg,
Germany. The certified parent input concentration as determined by the VERSANT® HIV-1 RNA 3.0 Assay
(bDNA) reference method was used to prepare the Subtype LOD-panels. Two independent dilution series of
the different HIV-1 subtypes were evaluated on two days with one lot of the COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test in a total of 24 replicates per concentration level for each subtype representative. The
results of the probit analyses at 95% hit rate demonstrate that the COBAS® AmpliPrep/COBAS® TaqMan®
HIV-1 Test has a sensitivity of ≤ 50 cp/mL across all subtypes ranging from < 15 to 46 cp/mL of HIV-1 group
M as shown in Table 4.
23
Table 4
Inclusivity as Limit of Detection of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test as
determined with cell-cultured viral stocks of the different HIV-1 subtypes diluted in EDTA plasma
95% hit rate conc. 95% Confidence Lowest level with

Subtype Isolate Designation
by probit model Interval [cp/mL] ≥ 95% hit rate
[cp/mL] Lower Upper [cp/mL]
A 92UG029 20 30
A 92UG037 52 50
A 4237A/98 < 15 15
A 92UG029/92UG037/
23 12 34 40
combined 4237A/98
HIV-1 Secondary
B 38 40
Standard (8E5 LAV)
B WHO 1st Int. Std. for 46 50

HIV-1 RNA (97/656)
B MVP-899-87 35 50
HIV-1 Secondary
Standard (8E5 LAV)/
B
WHO 1st Int. Std. for 40 33 50 50
combined
HIV-1 RNA (97/656)/
MVP-899-87
C 92BR025 16 30
C 98TZ017 50 50
C 3777A/97 16 15
C 92BR025/98TZ017/
31 25 41 40
combined 3777A/97
D 92UG021 35 40
D 92UG035 < 15 15
D 92UG024 17 30
D 92UG021/92UG035/
26 22 34 40
combined 92UG024
E 92TH022 < 15 15
E 92TH009 44 50
E 92TH001 34 50
E 92TH022/92TH009/
33 27 44 50
combined 92TH001
F 93BR020 46 34 82 40
G ARP173/RU570 < 15 NA NA 15
H ARP175/HIV V1557 < 15 NA NA 15
NA - not applicable (no analysis possible since the statistical software does not allow calculating a confidence interval
based on the observed hit rate profile)
E. Specificity
The clinical specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was determined by
analysis of HIV-1-negative EDTA plasma specimens from blood donors. A total of 513 individual EDTA
plasma specimens were tested. All specimens were negative for HIV-1 RNA. Based on these results, the
clinical specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is 100% with the confidence
interval ranging from 99.3 to 100%.
24
F. Analytical Specificity
The analytical specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was evaluated by
adding cultured organisms (viruses, bacteria, yeast) or DNA (HTLV-2) at 5E+04 particles/mL input con
centration into HIV-1-negative human EDTA plasma and into HIV-1-positive human EDTA plasma at 1E+04
cp/mL HIV-1 (see Table 5). The cultured organisms added to specimens have been shown not to inter
fere with the quantitation of HIV-1 RNA or impact the specificity of COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test.
Table 5
Analytical Specificity Organisms
Virus Bacteria
Adenovirus type 2 Staphylococcus aureus
Cytomegalovirus Propionibacterium acnes
Epstein-Barr Virus
Human Herpes Virus type 6
Herpes simplex virus type 1
Herpes simplex virus type 2
Human T-Cell Lymphotropic virus type 1 Yeast
Human T-Cell Lymphotropic virus type 2 Candida albicans
Influenza A
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
G. Method Correlation
The performance of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was compared to the
COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5, to the COBAS® AMPLICOR®
HIV-1 MONITOR Test, v1.5 and to the VERSANT HIV-1 RNA 3.0 Assay (bDNA) by analysis of n=71 undi
luted clinically characterized plasma specimens from HIV-1 infected patients. Specimens were obtained
from Teragenix (Fort Lauderdale, FL, USA). Correlation was determined using the specimens for which
quantitative results were obtained with each method under comparison. Specimens with a concentration
result above the measuring range of the COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR
Test, v1.5 using the ultrasensitive procedure (PHS) were prediluted to fall into the measuring range of the
PHS. Bivariate linear regression analysis was performed on those specimens that yielded results within
the linear range as shown in Figures 9, 10 and 11. The results obtained with the three methods under
comparison showed high correlation.
Figure 9
Correlation of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
and the COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5
7
COBAS® TaqMan® HIV-1 Test conc.)
6 y = 0.9621x + 0.0114
log 10 (COBAS® AmpliPrep/
2
R = 0.9603
5
1
1 2 3 4 5 6 7
log10 (COBAS® AmpliPrep/COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 conc.)
25
Figure 10
and the COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5
COBAS ® TaqMan® HIV-1 Test conc.)

6 y = 1.006x -0.0307
log 10 (COBAS® AmpliPrep/

2
R = 0.9262
5
1
1 2 3 4 5 6 7
® ®
log10 (COBAS AMPLICOR HIV-1 MONITOR Test, v1.5 conc.)
Figure 11
and the VERSANT HIV-1 RNA 3.0 Assay (bDNA)
7
COBAS ® TaqMan ® HIV-1 Test conc.)
6 y = 0.960x + 0.292
log 10 (COBAS®AmpliPrep/
2
R = 0.954
5
1
1 2 3 4 5 6 7
log 10 (VERSANT HIV-1 RNA 3.0 Assay)
26
CLINICAL PERFORMANCE EVALUATION

A. Reproducibility
This study was conducted to evaluate the reproducibility of the COBAS® AmpliPrep/COBAS® TaqMan®
HIV-1 Test in EDTA plasma. Well characterized HIV-1 group M, subtype B virus stock cultures and EDTA
plasma that was negative for HIV-1 RNA and HIV 1/2 antibodies were used to construct a 10-member
panel. The study was designed to measure inter-run, intra-run, lot to lot, day to day, site to site, and oper
ator to operator variability. Each panel was tested by multiple operators at each of three sites; one internal
Roche Molecular Systems, Inc. (RMS) site, and two sites external to RMS. Each operator performed 5
days of testing on each of 3 lots of reagents with each panel. Each operator was to complete 1 run per
day. Each run comprised a single panel with each panel member tested in duplicate.
Precision was evaluated using a random effects model with terms for lot, site/instrument, operator within
site, between day/run and within-run components.
Table 6 shows the total precision variance and total precision standard deviation as determined by
analysis of variance. Analysis of variance provides an estimate of the total precision of the test that prop
erly weights the between-lot, between-site/instrument, between-operator, between-day/run (day-to-day)
and within-run components. The total precision reported as lognormal variance was less than 35% for
all panel members except the panel member with the lowest concentration (100 copies/mL). The within-
run component contributed the most variability (56% to 100%), followed by lot-to-lot variability. The
site/instrument, operator and day/run components contributed less to variability.
Table 7 summarizes the results for the HIV-1 Negative Panel Member. The negative panel member was
used to estimate the analytical specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test. One
false positive result was observed out of 179 valid test results giving a specificity of 99% [95% Confidence
Interval (CI) = (0.97, 1.00)].
Table 6
Reproducibility Results Summary
HIV-1 RNA Concentration

Contribution to Total Variance (%) Total Precision
(log10 cp/mL)
Observed Site / Within Standard Deviation
Expected N Lot Operator Day / Run
(Average) Instrument Run (Lognormal %CV)
2.000 2.020 147 0% 0% 0% 0% 100% 0.19 (46%)

2.699 2.743 173 2% 6% 4% 20% 68% 0.14 (34%)
3.000 2.995 178 0% 8% 0% 8% 84% 0.14 (32%)
3.699 3.743 178 16% 5% 3% 18% 57% 0.14 (34%)
4.301 4.410 179 14% 6% 2% 5% 74% 0.14 (32%)
4.699 4.836 178 21% 1% 0% 2% 76% 0.12 (29%)
5.398 5.501 178 32% 0% 0% 6% 62% 0.13 (31%)
5.699 5.837 178 28% 0% 0% 3% 68% 0.14 (34%)
6.699 6.871 108 32% 4% 0% 9% 56% 0.13 (30%)
Note: Within assay range results are from 4.80E+1 cp/mL to 1.00E+7 cp/mL inclusive.
Table 7
HIV-1 Negative Panel Member Summary
Target Analytical Exact

Total Valid Results Target Detected
Not Detected Specificity 95% CI
179 178 1 0.99 (0.97, 1.00)
27
Clinical Sensitivity and Specificity

Methodology
This study was designed to evaluate the clinical specificity and sensitivity of the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test by testing fresh and frozen samples collected from normal
healthy donors and patients with HIV-1. This study compared Test results obtained with the COBAS®
AmpliPrep/COBAS® TaqMan® HIV-1 Test to those obtained with an FDA-approved test, ie, the COBAS®
AMPLICOR® HIV-1 MONITOR Test, v1.5. Clinical specificity of the COBAS® AmpliPrep/COBAS® TaqMan®
HIV-1 Test was evaluated by testing 399 frozen samples and 120 fresh samples, in EDTA plasma, col
lected from normal healthy blood donors who were negative for HIV-1 antibodies. Frozen samples were
randomly distributed across testing sites. Fresh samples were distributed to testing sites in a non-random
manner. Clinical sensitivity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was evaluated testing
351 frozen samples with HIV-1 RNA concentrations ≥50 cp/mL and 122 fresh samples in EDTA plasma,
collected from HIV-1-positive blood donors. Frozen samples were randomly distributed across testing sites,
stratified by CD4 count category. Fresh samples were distributed to testing sites in a non-random manner.
Frozen samples used in this study were previously tested with COBAS® AMPLICOR® HIV-1 MONITOR
Test, v1.5 and, therefore, were not retested in this study on that platform. Collection of frozen normal donor
(HIV-1-negative) samples occurred at 4 sites: 1 each in Tennessee, Florida, Pennsylvania, and California.
Collection of frozen HIV-1-positive samples occurred at 6 sites: 1 each in California, New Jersey, Maryland,
and Missouri, and at 2 sites in Florida. Collection of fresh samples occurred at 5 sites, as follows: HIV-1
positive samples were collected at 4 sites: 2 in Florida, 2 in California; samples from normal healthy donors
were collected at 1 site in Tennessee. Fresh samples collected for this study were tested prospectively on
the COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 platform. Testing was performed at 3 sites, with 1
COBAS® AmpliPrep/COBAS® TaqMan® 48 Analyzer system per site, with at least 3 reagent lots.
Statistical Methods
Normal subjects were considered evaluable if they contributed both valid COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test and COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 results (where the COBAS®
AMPLICOR® HIV-1 MONITOR Test, v1.5 result was Target Not Detected). HIV-1 subjects were considered
evaluable if they contributed both valid COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test and COBAS®
AMPLICOR® HIV-1 MONITOR Test, v1.5 results (where the COBAS® AMPLICOR® HIV-1 MONITOR Test,
v1.5 result was ≥50 cp/mL).
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical specificity was calculated as the percentage
(95% exact confidence interval [CI]) of normal subjects with Target Not Detected COBAS® AMPLICOR®
HIV-1 MONITOR Test, v1.5 results, who had Target Not Detected COBAS® AmpliPrep/COBAS® TaqMan®
HIV-1 Test results. COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical specificity was calculated
overall and by sample type (fresh and frozen separately).
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical sensitivity was calculated as the percentage
(95% exact CI) of HIV-1 subjects with COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 results ≥50
cp/mL, who had detectable HIV-1 viral load on the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test.
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical sensitivity was calculated overall and by CD4
count category (<200, 200-500, >500 cells/µL) and sample type (fresh and frozen separately).
Results
Table 8 summarizes the number of fresh and frozen samples from evaluable normal and HIV-1 subjects
in this study.
Table 8
Number of Evaluable Normal and HIV-1 Subjects by Sample Type
Sample Type Normal Subjects HIV-1 Subjects Total

Fresh 120 (23.1%) 122 (25.8%) 242
Frozen 399 (76.9%) 351 (74.2%) 750
Total 519 473 992
Table 9 shows the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical specificity results from the
519 evaluable normal subjects. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical speci
ficity was 99.4% (516/519; 95% CI = 98.3% to 99.9%). The HIV-1-positive COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test results were all <40 cp/mL.
28
Table 9
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test Specificity - Evaluable Normal Subjects
® ® ® ®
® COBAS AmpliPrep/COBAS TaqMan HIV-1 COBAS
COBAS ®
® Test Result AmpliPrep/COBAS
AMPLICOR ®
TaqMan HIV-1 Test
HIV-1 MONITOR Total
Clinical
Test, v 1.5 HIV-1 Positive HIV-1 Negative Specificity
Result
(95% Exact CI)
99.4%
HIV-1 Negative 3 (0.6%) 516 (99.4%) 519
(98.3%, 99.9%)
Note: CI = Confidence Interval
Table 10 shows the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical sensitivity results from the
473 evaluable HIV-1 subjects. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical sensitivity
was 98.3% (465/473; 95% CI = 96.7% to 99.3%).
Table 10
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test Sensitivity - Evaluable HIV-1 Subjects
® ® ® ®
® COBAS AmpliPrep/COBAS TaqMan HIV-1 COBAS
COBAS ®
® Test Result AmpliPrep/COBAS
AMPLICOR ®
TaqMan HIV-1 Test
HIV-1 MONITOR Total
Clinical
Test, v1.5 HIV-1 Positive HIV-1 Negative Sensitivity
Result
(95% Exact CI)
HIV-1 Positive 465 (98.3%) 8 (1.7%) 473 98.3%
(96.7%, 99.3%)
*All 8 samples that were determined to be positive for HIV-1 by COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 but
not by COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test had a low copy number: 6 of the 8 had HIV-1 titers of < 100
cp/mL, 1 had a titer of 253 cp/mL, and the remaining sample had a titer of 479 cp/mL.
Table 11 shows the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test clinical sensitivity by CD4 count
category (<200, 200-500, >500 cells/µL).
Table 11
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test Sensitivity by CD4 Count Category -
Evaluable HIV-1 Subjects
® ® ® ® ®
COBAS COBAS AmpliPrep/COBAS TaqMan COBAS
® ®
AMPLICOR HIV-1 Test Result AmpliPrep/COBAS
CD4 Count ®
HIV-1 TaqMan HIV-1 Test
Category Total
MONITOR Clinical
(cells/µL) HIV-1 Positive HIV-1 Negative
Test, v1.5 Sensitivity
Result (95% Exact CI)
99.3%
<200 HIV-1 Positive 141 (99.3%) 1 (0.7%) 142
(96.1%, 100.0%)
98.6%
200 – 500 HIV-1 Positive 212 (98.6%) 3 (1.4%) 215
(96.0%, 99.7%)
96.6%
>500 HIV-1 Positive 112 (96.6%) 4 (3.4%) 116
(91.4%, 99.1%)
29
Conclusion
When compared with results from the COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5, clinical speci
ficity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was 99.4%, and clinical sensitivity was
98.3%, indicating similar performance of both tests. Furthermore, in both fresh and frozen samples, the
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test showed similar specificity (>98%) and sensitivity
(>98%), indicating comparable test performance for both sample types.
Selection of the HIV-1 samples included in this study was based on a single test result with the COBAS®
AMPLICOR® HIV-1 MONITOR Test, v1.5. For low titer samples, the results from the COBAS®
AMPLICOR® HIV-1 MONITOR Test, v1.5 are subject to large variability (coefficient of variation = 50% at
100 cp/mL). All 8 samples that were determined to be positive for HIV-1 by the COBAS® AMPLICOR®
HIV-1 MONITOR Test, v1.5 but not by the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test had a low
copy number: 6 of the 8 had HIV-1 titers of <100 cp/mL, 1 had a titer of 253 cp/mL, and the remaining
sample had a titer of 479 cp/mL. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test was able to
detect 111 out of the 119 samples with titers <480 cp/mL. The observed results are consistent with what
is expected with low-titer samples. Furthermore, the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
and the COBAS® AMPLICOR® HIV-1 MONITOR Test, v1.5 appeared to show comparable agreement
across the linear range.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test also showed similar clinical sensitivity among
CD4 count categories (>96% overall), suggesting comparable performance in samples from HIV-1 patients
with various CD4 counts.
30
REFERENCES
1. Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, C.,
Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., Montagnier, L. 1983. Isolation of a
T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
Science 220:868-871.
2. Popovic, M., Sarngadharan, M.G., Read, E., Gallo, R.C. 1984. Detection, isolation, and continuous
production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science
224:497-500.
3. Gallo, R.C., Salahuddin, S.Z., Popovic, M., Shearer, G.M., Kaplan, M., Haynes, B.F., Palker, T.J.,
Redfield, R., Oleske, J., Safai, B., White, G., Foster, P., Markham, P.D. 1984. Frequent detection
and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.
Science 224:500-503.
4. Curran, J.W., Jaffe, H.W., Hardy, A.M., Morgan, W.M., Selik, R.M., Dondero, T.J. 1988. Epidemiology
of HIV Infection and AIDS in the United States. Science 239:610-616.
5. Gaines, H., von Sydow, M.A., von Stedingk, L.V. 1990. Immunological changes in primary HIV-1
infection. AIDS 4:995-999.
6. Tindall, B., and Cooper, D.A. 1991. Primary HIV-1 infection: host responses and intervention strate
gies. AIDS 5:1-14.
7. Daar, E.S., Moudgil, T, Meyer. R.D., Ho, D.D. 1991. Transient high levels of viremia in patients with pri
mary human immunodeficiency virus type 1 infection. New England Journal of Medicine 324:961-964.
8. Clark, S.J., Saag, M.S., Decker, W.D. 1991. High titers of cytopathic virus in plasma of patients
with symptomatic primary HIV-1 infection. New England Journal of Medicine 324:954-960.
9. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., Fenyo E.M. 1990. Rapid
development of isolate-specific neutralizing antibodies after primary HIV-1 infection and conse
quent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
10. Horsburgh, C.R. Jr., Ou, C.Y., Jason, J., Holmberg, S.D., Longini, I.M. Jr., Schable, C., Mayer, K.H.,
Lifson, A.R., Schochetman, G., Ward, J.W, et al. 1989. Duration of human immunodeficiency virus
infection before detection of antibody. Lancet 16:637-640.
11. Schnittman, S.M., Psallidopoulos, M.C., Lane, H.C., Thompson, L., Baseler, M., Massari, F., Fox, C.H.,
Salzman, N.P., Fauci, A.S. 1989. The reservoir for HIV-1 in human peripheral blood is a T cell that
maintains expression of CD4. Science 245:305-308. Erratum in: Science 1989 245, preceding 694.
12. Schnittman, S.M., Greenhouse, J.J., Psallidopoulos, M.C., Baseler, M., Salzman, N.P., Fauci, A.S.,
Lane, H.C. 1990. Increasing viral burden in CD4+ T cells from patients with human immunodefi
ciency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease.
Annals of Internal Medicine 113:438-443.
13. Pantaleo, G., Graziosi, C., Fauci, A.S. 1993. New concepts in the immunopathogenesis of human
immunodeficiency virus (HIV) infection. New England Journal of Medicine 328:327-335.
14. Piatak, M. Jr., Saag, M.S., Yang, L.C., Clark, S.J., Kappes, J.C., Luk, K.C., Hahn, B.H., Shaw, G.M.,
Lifson, J.D. 1993. High levels of HIV-1 in plasma during all stages of infection determined by com
petitive PCR. Science 259:1749-1754.
15. Fauci, A.S., Schnittman, S.M., Poli, G., Koenig, S., Pantaleo, G. 1991. NIH conference:
immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Annals of
Internal Medicine 114:678-693.
16. Coffin, J.M. 1995. HIV-1 population dynamics in vivo: Implications for genetic variation, patho
genesis, and therapy. Science 267:483-489.
17. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M. 1995. Rapid
turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
18. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer,
S., Nowak, M.A., Hahn, B.H., et al. 1995. Viral dynamics in human immunodeficiency virus type 1
infection. Nature 373:117-122.
31
19. O'Brien, W.A., Hartigan, P.M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff,
M.S., Hamilton, J.D. 1996. Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the
risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. New England
Journal of Medicine 334:426-431.
20. Welles, S.L., Jackson, J.B., Yen-Lieberman, B., Demeter, L., Japour, A.J., Smeaton, L.M., Johnson,
V.A., Kuritzkes, D.R., D'Aquila, R.T., Reichelderfer, P.A., Richman, D.D., Reichman, R., Fischl, M.,
Dolin, R., Coombs, R.W., Kahn, J.O., McLaren, C., Todd, J., Kwok, S., Crumpacker, C.S. 1996.
Prognostic value of plasma Human Immunodeficiency Virus Type I (HIV-1) RNA levels in patients
with advanced HIV-1 disease and with little or no zidovudine therapy. AIDS Clinical Trials Group
Protocol 116A/116B/117 Team. Journal of Infectious Diseases 174:696-703.
21. Coombs, R.W., Welles, S.L., Hooper, C., Reichelderfer, P.S., D'Aquila, R.T., Japour, A.J., Johnson,
V.A., Kuritzkes, D.R., Richman, D.D., Kwok, S., Todd, J., Jackson, J.B., DeGruttola, V., Crumpacker,
C.S., Kahn, J. 1996. Association of plasma Human Immunodeficiency Virus Type I RNA level with
risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG)
116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
Journal of Infectious Diseases 174:704-712.
22. Hammer, S., Crumpacker, C., D'Aquila, R., Jackson, B., Lathey, J., Livnat, D., Reichelderfer, P. 1993.
Use of virologic assays for detection of human immunodeficiency virus in clinical trials:
Recommendations of the AIDS Clinical Trials Group Virology Committee. Journal of Clinical
Microbiology 31:2557-2564.
23. Schochetman, G., George, J.R., ed. AIDS testing: a comprehensive guide to technical, medical,
social, legal and management issues. 2nd ed. New York: Springer-Verlag, 1994.
24. Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., Kwok, S. 1994. Rapid
and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma:
Application to acute retroviral infection. Journal of Clinical Microbiology 32:292-300.
25. Dewar, R.L., Highbarger, H.C., Sarmiento, M.D., Todd, J.A., Vasudevachari, M.B., Davey, R.T. Jr.,
Kovacs, J.A., Salzman, N.P., Lane, H.C., Urdea, M.S. 1994. Application of branched DNA signal
amplification to monitor human immunodeficiency virus type 1 burden in human plasma. Journal
of Infectious Diseases 170:1172-1179.
26. van Gemen, B., Kievits, T., Schukkink, R., van Strijp, D., Malek, L.T., Sooknanan, R., Huisman, H.G.,
Lens, P. 1993. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection.
Journal of Virological Methods 43:177-187.
27. Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A., Arnheim, N. 1985.
Enzymatic amplification of b-globin genomic sequences and restriction site analysis for diagnosis
of Sickle Cell Anemia. Science 230:1350-1354.
28. Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B., Erlich, H.A.
1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science 239:487-491.
29. Mullis, K.B., Faloona, F.A. 1987. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain
reaction. Methods in Enzymology 155:335-350.
30. Q. Meng, C. Wong, A. Rangachari, S. Tamatsukuri, M. Sasaki, E. Fiss, L. Cheng, T. Ramankutty, D.
Clarke, H. Yawata, Y. Sakakura, T. Hirose, and C. Impraim. 2001. Automated Multiplex Assay System
for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human
Immunodeficiency Virus Type 1 RNA. Journal of Clinical Microbiology 39 (8):2937-2945.
31. Smith, E.S., Li, A.K., Wang, A.M., Gelfand, D.H., Myers, T.M. 2003. Amplification of RNA: High-
Temperature Reverse Transcription and DNA Amplification with a Magnesium-Activated Thermostable
DNA Polymerase. In PCR Primer: A Laboratory Manual, 2nd Edition, Dieffenbach C.W. and Dveksler
G.S., Eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 211-219.
32. Kwok, S., Sninsky, J.J. 1993. PCR detection of human immunodeficiency virus type 1 proviral DNA
sequences. In: Diagnostic Molecular Biology: Principles and Applications. eds. Persing, D.H.,
Smith, T.F., Smith, F.C., et al. ASM, Washington, D.C.
33. Longo, M.C., Berninger, M.S., Hartley, J.L. 1990. Use of uracil DNA glycosylase to control carry
over contamination in polymerase chain reactions. Gene 93:125-128.
32
34. Higuchi, R., Dollinger, G., Walsh, P.S., Griffith, R. 1992. Simultaneous amplification and detection
of specific DNA sequences. Biotechnology (N Y). 10:413-417.
35. Heid, C.A., Stevens, J., Livak, J.K., Williams, P.M. 1996. Real time quantitative PCR. Genome
Research 6:986-994.
36. Holmes, H., Davis, C., Heath, A., Hewlett, I. and Lelie, N. 2001. An international collaborative study
to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques.
Journal of Virological Methods 92:141-150.
37. Richmond, J.Y. and McKinney, R.W. eds. 1999. Biosafety in Microbiological and Biomedical
Laboratories. HHS Publication Number (CDC) 93-8395.
38. CLSI. Protection of Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids,
and Tissue. Approved Guideline. CLSI Document M29-A Villanova, PA: CLSI 1997.
39. International Air Transport Association. Dangerous Goods Regulations, 41st Edition. 2000. 704 pp.
40. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish
ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen
M, Sharp PM, Wolinsky S, and Korber B: HIV-1 Nomenclature proposal: A reference guide to HIV
1 classification. In: Human Retroviruses and AIDS 1999: A Compilation and Analysis of Nucleic
Acid and Amino Acid Sequences (Kuiken C, Foley B, Hahn B, Korber B, McCutchan F, Marx PA,
Mellors JW, Mullins JI, Sodroski J, and Wolinsky S, eds.). Theoretical Biology and Biophysics
Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1999, pp. 492-505.
41. CLSI. Evaluation of Precision Performance of Clinical Chemistry Devices. Approved Guideline. CLSI
Document EP5-A. Wayne, PA: CLSI 1999.
33
34
35
" Roche Molecular Systems, Inc., Branchburg, NJ, 08876 USA

A Member of the Roche Group
Roche Diagnostics Roche Diagnostics

Indianapolis, IN 46256 USA H7V 4A2 Laval, Quebec
(For Technical Assistance call the (For Technical Assistance call:
Distributed by Roche Response Center Pour toute assistance technique,
toll-free: 1-800 526 1247) appeler le: 1-877 273 3433)
Roche Diagnostics (Schweiz) AG Roche Diagnostics
CH-6343 Rotkreuz F-38240 Meylan
Roche Diagnostics GmbH Distributore in Italia:
D-68298 Mannheim, Germany Roche Diagnostics SpA
Piazza Durante 11
I-20131 Milano
Roche Diagnostics S.L. Distribuidor em Portugal:
E-08006 Barcelona Roche Farmacêutica Química, Lda
P-2700 Amadora
ROCHE, AMPERASE, AMPLICOR, AMPLILINK, COBAS, AMPLIPREP, TAQMAN and HIGH PURE are
trademarks of Roche.
ROCHE RESPONSE CENTER is a service mark of Roche.
Armored RNA is a patented technology jointly developed by Ambion, Inc. and Cenetron Diagnostics, LLC.
U.S. patents #5,677,124, #5,919,625, and #5,939,262 and patents pending. Armored RNA® is a reg
istered trademark of Ambion and Cenetron.
Microsoft and Windows XP are either registered trademarks or trademarks of Microsoft Corporation in
the United States and/or other countries.
ProClin is a trademark of Rohm and Haas Company.
VERSANT® is a registered trademark of Bayer Corporation.
Copyright 2007, Roche Molecular Systems, Inc. All rights reserved.

5/2007 03542904001-01
Doc Rev. 1.0
36

Cobas Ampliprep/Cobas Taqman Hiv-1 Test: For in Vitro Diagnostic Use

Uploaded by

Copyright:

Available Formats

Cobas Ampliprep/Cobas Taqman Hiv-1 Test: For in Vitro Diagnostic Use

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cobas Ampliprep/Cobas Taqman Hiv-1 Test: For in Vitro Diagnostic Use

Uploaded by

Copyright:

Available Formats

COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test

FOR IN VITRO DIAGNOSTIC USE.

PRINCIPLES OF THE PROCEDURE

detected by cleavage of a target-specific and a QS-specific dual-labeled oligonucleotide probe.

Fundamentals of COBAS® TaqMan® Test Quantitation

Target Growth Curves for a Dilution Series Spanning a 5-log10 Range

3.00 Highest Titer

1.00 Lowest Titer

that Spans a 5-log10 Range

30.00 Lowest Titer

5.00 Highest Titer

Normalization of Fluorescence Values at Every Cycle for Each Growth Curve

Normalized Fluorescence 0.8 Assigned Fluorescence Ct Value = 27.1

HIV-1 RNA Quantitation

42.5% Guanidine thiocyanate

< 14% Polydocanol

< 0.04% dATP, dCTP, dGTP, dUTP, dTTP

< 0.003% Upstream and downstream primers to the GAG

< 0.003% Oligonucleotide aptamer

< 0.003% Fluorescent-labeled oligonucleotide probes

specific for HIV-1 and the HIV-1 QS

< 0.05% Z05 DNA Polymerase (microbial)

< 0.1% AmpErase (uracil-N-glycosylase) enzyme (microbial)

0.09% Sodium azide

CAP/CTM Mn2+ 1 x 19.8 mL

Glacial acetic acid

0.09% Sodium azide

HIV-1 H(+)C 4 x 1.0 mL

for antibody to HCV, antibody to HIV-1/2, HIV p24 antigen

0.1% ProClin® 300 preservative

sequences (non-infectious RNA in MS2 bacteriophage) at a mean

concentration at least 100 fold lower than the mean concentration

of Armored HIV-1 RNA in HIV-1 H(+)C

Negative Human Plasma, non-reactive by FDA licensed tests for

antibody to HCV, antibody to HIV-1/2, HIV p24 antigen and HBsAg;

0.1% ProClin® 300 preservative

antibody to HCV, antibody to HIV-1/2, HIV p24 antigen and HBsAg;

0.1% ProClin® 300 preservative

< 0.1% N-Methylisothiazolone-HCl

WARNINGS AND PRECAUTIONS

STORAGE AND HANDLING REQUIREMENTS

MATERIALS REQUIRED BUT NOT PROVIDED

• COBAS® TaqMan® Analyzer HIV-1 PCR TEST FILE CD ROM

HIV-1 Stability in Whole Blood with EDTA Anticoagulant

HIV-1 Stability in EDTA-Plasma

HIV-1 Results after up to Five Freeze/Thaw Cycles

INSTRUCTIONS FOR USE

Part B. Loading of Reagent Cassettes

Possible Configurations for using COBAS® AmpliPrep Instrument with

COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer

Transfer mode to Position on

Part D. Ordering and Loading of Specimens

Amplification and Detection

Configuration 2 and 5: Manual transfer of K-tubes in sample rack(s) to COBAS® TaqMan®

Configuration 3, 4 and 5: Manual transfer of K-carrier on K-carrier rack(s) to the COBAS®

NOTE: Caution! K-carrier may be hot after cycling.

Control Result Interpretation

HIV-1 Low Positive Control:

Flag Result Interpretation